App Note: FDA-Accepted Monoclonality Assurance on the Beacon® Optofluidic System for Cell Line Development
Learn how the Beacon system’s superior cloning technology, automated imaging capabilities, and in-process quality controls provide definitive evidence of monoclonality to support regulatory approvals.
Related Resources
View All ResourcesApp Note: Bring Product Quality Assessment into Early Clone Selection with the Opto™ Assure Aggregation Assay
Read this application note to learn more about how to get early, multi-parameter assessment of clones with the Opto Assure assay series.
Webinar: Bring Product Quality Assessment into Early Clone Selection with Opto™ Cell Line Development
CHO cell line selection represents a painful bottleneck in biotherapeutic development, particularly for complex molecules like bispecifics. At BPI Europe Digital Week 2021, Renee Tobias discussed how the Opto™ CLD workflow on the Beacon® system can help through accelerating early CLD by integrating high throughput cell sorting, cloning, culture, productivity, growth, and product quality assays into a single, 5-day automated process.
Fireside Chat: Every Day Matters – Optimizing COVID-19 Therapies for Manufacturing
Dr. James Rothman, Nobel Laureate hosts an in-depth discussion with distinguished guests, Dr. Jennitte Stevens from Amgen, Dr. Gregory Bleck from Catalent-Biologics, and Dr. Trent Munro from the University of Queensland on fast-tracking the development of therapeutic antibodies and vaccines for SARS-CoV-2.